Sustained remission in a patient with PDGFR-beta-rearranged T-lymphoblastic lymphoma and complete remission with dasatinib

Pediatr Blood Cancer. 2020 Jan;67(1):e28026. doi: 10.1002/pbc.28026. Epub 2019 Oct 1.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Child
  • Dasatinib / therapeutic use*
  • Gene Rearrangement*
  • Humans
  • Male
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Prognosis
  • Receptor, Platelet-Derived Growth Factor beta / genetics*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Receptor, Platelet-Derived Growth Factor beta
  • Dasatinib